Methylation Status and Expression of E-cadherin in Oral Squamous Cell Carcinomas Compared to Benign Oral Epithelial Lesions

Son, Hyun-Jin,Chu, Jung-Youb,Cho, Eui-Sic,Lee, Dong-Geun,Min, Myung-Gee,Lee, Suk-Keun,Cho, Nam-Pyo The Korean Academy of Oral Biology 2006 International Journal of Oral Biology Vol.31 No.2

Expression of invasion/metastasis suppressor, E-cadherin, is reduced in many types of human carcinomas. Although somatic and germline utations in the CDH1, which encodes the human E-cadherin, have frequently been reported in cases with diffuse gastric and lobular breast ancers, irreversible genetic inactivations are rare in other human carcinomas. Recently, it has been well documented that some genes in human cancers may be inactivated by altered CpG methylation. Herein, we determined the expression and methylation status of E-cadherin in oral squamous cell carcinoma (SCC) by immunohistochemistry and methylation-specific PCR. The expression of E-cadherin was significantly higher in the well-differentiated oral SCCs than the moderately or poorly differentiated ones. None of eight tested benign pithelial hyperplasias showed aberrant methylation, whereas five of 12 oral squamous cell carcinomas showed aberrant methylation. When we compared E-cadherin expression with methylation status, oral SCCs with normal methylation showed a higher expression of E-cadherin than those with methylation. These findings suggest that aberrant CpG methylation of CDH1 promoter region is closely associated with transcriptional inactivation and might be involved in tumor progression of the oral mucosa.

아마릴 정(글리메피리드 2㎎)에 대한 글리메드 정의 생물학적 동등성

조혜영,박은자,강현아,백승희,이석,김세미,문재동,이용복 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.2

The purpose of the present study was to evaluate the bioequivalence of two glimepiride tables, Amaryl^(?)(Handok/Aventis Pharm. Co., Ltd.) and Glimed (Kuhn Ⅱ Pharm. Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The glimepiride release from the two glimepiride formulations in vitro was tested using KP Ⅷ Apparatus Ⅱ method with a variety of dissolution media (pH 1.2, 4.0, 6.8 buffer solution, water and blend of PSB 80 into each dissolution medium). Twenty six healthy male subjects, 22.65±2.19 years in age and 66.55±8.85 kg in body weight, were divided into two groups and randomized 2×2 cross-over study was employed. After one tablet containing 2 ㎎ as glimepiride was orally administered, blood was taken at predetermined time intervals and the concentrations of glimepiride in serum were determined using HPLC method with UV detctor. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_(t), C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Amaryl were -3.70, -8.28 and 0.61% for AUC_(t), C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25)(e.g., log(0.84)∼log(1.04) and log(0.82)∼log(1.03) for AUC_(t) and C_(max), respectively). Thus, the criteria of the KFDA guideline for the bioequivalence were satisfied, indicating Glimed tablet and Amaryl tablet were bioequivalent.

양파(Allium cepa L.) 추출물이 Tyrosinase 유전자 발현에 미치는 효과

조남철,윤연희,이혜진,손현정,김양경,최근희,나명석,조영권,이황희,진종언 한국식품영양학회 2001 韓國食品營養學會誌 Vol.14 No.3

Melanin 생성에 관여하는 tyrosinase 유전자의 발현을 억제하는 물질을 탐색하고자 tyrosinase promoter를 지닌 Bl6 mouse melanoma cell해 앙파 methanol 추출물을 처리한 바 양파 methanol 추풀물은 10.0㎍/ml, 100.0 ㎍/ml, 1.0 ㎎/ml의 농도에서 대조군에 비해서 약 15%, 23% 57%의 억제효과를 나타냈으며 세포생존율은 1.0 ㎍/ml, 10.0 ㎍/ml, I00.0 ㎍/ml, 1.0㎎/ml의 농도에서 약 126 %, 92%. 85%, 64%로서 세포독성이 낮게 나타났다. Ethyl acetate, butyl alcohol, 그리고 물 용매 분획물은 tyrosinase 유전자의 발현물 억제하는 효과가 없었지만 methylene chloride 용해 분획물은 10.0 ㎍/ml과 100.0 ㎍/ml의 농도에서 약 37%와 35%의 발현율을 나타냄으로서 대조군에 비해 크게 억제하였다. Onion(Allium cepa L,) extract by methanol repressed the expression of tyrosinase gene of B16 mouse melanoma cell containing tyrosinase promoter. 10.0 ㎍/ml, 100.0 ㎍/ml, 1.0 ㎎/ml of the extract repressed expression of tyrosinase gene about 15%, 23%, and 57%, respectively, compared with control. In the MTT assay, the same extract exhibited low cytotoxicity at 1.0 ㎍/ml, 10.0 ㎍/ml, 100.0 ㎍/ml, and 1.0 ㎎/ml, respectively. The fractions of ethyl acetate, butyl alcohol, and water did not showed the repressive effect on the expression of tyrosinase gene, but the fraction of methylene chloride repressed highly at 10.0 ㎍/ml and 100.0 ㎍/ml.

유방암의 위와 대장전이

유현아,김은영,서민지,정은,조민정,오현진,장지혜,박지찬,이정의,박석영 이화여자대학교 의과학연구소 2014 EMJ (Ewha medical journal) Vol.37 No.2

Gastric metastasis from breast cancer is rare and only six cases have been reported in Korea. Colon metastasis is more rare than gastric metastasis. We report a 63-year-old woman with gastric and colon metastases of invasive lobular carcinoma of breast. She was diagnosed as right breast cancer, received right modified radical mastectomy 10 years ago and has been treated with chemotherapy and hormone therapy. Investigating for melena and a small caliber of stool, we found gastric and colon metastases. The diagnosis of metastatic breast cancer was made through gross pathologic and immunohistochemistry staining. We report a case with gastric and colon metastases from breast cancer and a review of the associated six case reports in Korea.

엘도스 캡슐(에르도스테인 300mg)에 대한 엘브론 캡슐의 생물학적 동등성

조혜영,이석,강현아,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.3

Erdosteine, the thiol derivatives chemically related to cysteine, is a mucolytic and mucoregulator agent which modulated mucus production and viscosity and increases mucoiliary transport. The purpose of the present study was to evaluate the bioequivalence of two erdosteine capsules, Erdos (Dae Woong Pharmaceutical Co., Korea) and Erblon (Kuhn Ⅱ Pharmaceutical Co., Korea), according to the guidelines of Korea Food and Drug Administration (KFDA). The erdosteine release from the two erodisteine capsules in vitro was tested using KP Ⅷ Apparatus Ⅱ method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four healthy male subject, 23.33±2.06 years in age and 66.18±8.19 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three capsules containing 300 ㎎ as erdostein were orally administered, blood was taken at predetermined time intervals and the concentrations of erdostein in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_(t), C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using log-arithmically transformed AUC_(t) and C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Erdos were 0.20%, 1.10% and -9.44% for AUC_(t), C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of long(0.8) to log(1.25)(e.g., long(0.94)∼long(1.22) and log(0.92)∼log(1.20) for AUC_(t) and C_(max), respectively. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Erblon capsule and Erdos capsule are bioequivalent.

파노라마방사선사진 지수와 임플란트 실패와의 관계에 관한 연구

조현정,이원진,허민석,안창현,이진구,이삼선,최순철 大韓口腔顎顔面 放射線學會 2004 Imaging Science in Dentistry Vol.34 No.1

Purpose : Several panoramic indices have been suggested to assess bone quality from the morphology and width of mandibular cortex on panoramic radiography. The purpose of this study was to compare dental implant failure group with control group in panoramic mandibular index (PMI), mandibular cortical index (MCI), and gonion index (GI) and to determine the effect of these panoramic indices on dental implant failure. Materials and Methods : A case-control study was designed. Test group (n = 42) consisted of the patients who had their implants extracted because of peri-implantitis. Control group (n = 139) consisted of the patients who retained their implants over one year without any pathologic changes and had been followed up periodically. They had dental implants installed in their mandibles without bone augmentation surgery from 1991 to 2001. The following measures were collected for each patients: 1) PMI, MCI, and GI were measured twice at one-week interval on preoperative panoramic views; and 2) age, sex, implant length, implant type, installed location, occluding dentition state, and complication were investigated from the chart record. Results : The PMI showed moderate level of repeatability. The intra-observer agreement of MCI and GI were good. There was statistically significant difference in PMI between two groups. There were significant different patterns of distribution of MCI and GI between two groups. Among the panoramic indices, PMI and MCI showed significant correlation with dental implant failure. Conclusion : Panoramic indices can be used as reference data in estimating bone quality of edentulous patients who are to have implants installed in their mandibles.

백서피부의 화상 손상에 따른 효소조직화학적 변화

조백현,김영길,허우회,최석현 大韓成形外科學會 1983 Archives of Plastic Surgery Vol.10 No.2

The purpose of this study was to investigate the sequential changes of enzyme activities in severely burned skin of rat at intervals of 2 hours, 8 hours, 1 day and 3 days by histochemical methods. The results obtained were as follows. 1. Acid phosphatase activity was found to be transient increase in dermis and mild decrease in epidermis, hair follicle and sebaceous gland at 2 hour after burning. The activity was not seen in skin after 8 hours. 2. Alkaline phosphatase was found to be decreased in blood vessel and dermal papillae of hair follicle at 2 hour after burning and then was progressively decreased after 8 hours. 3.α-naphtyl acetate esterase activity was found to be decreased in epidermis, dermis and hair follicle at 2 hours after burning and was not seen in skin after 8 hours. There was no significant changes in sebaceous gland after burning.

투기종목 선수들의 무산소성 역치의 특성

조현철,송순천,김춘경,김의영,안용규,이규석,김학렬 龍仁大學校 體育科學硏究所 1991 體育科學硏究論叢 Vol.1 No.1

The purpose of the present study is to determine the levels of maximal oxygen uptake and anaerobic threshold of boxing players(n=23), ken-do players(n=18), Judo players(n=12), T.D.K players(n=18). Treadmill test was used to measure maximal state and anaerobic threshold of metabolic variables. Treadmill exercises protocol was 2-min incremental test from an initial work load of 0MPH(grade : 0%) to all-out by step of 1.0MPH(grade : 2%). The results of measurement was as follows : 1. Absolute(1/min) and relative(ml/kg/min) maximal oxygen uptake was highest(5.08l/min, 65.01 ml/kg/min) in Judo layers, followed in order by the T.D.K players (4.37l/min, 64.74 ml/kg/min), Boxing players(4.18) l/min, 63.19 ml/kg/min) and ken-do players(3.81l/min, 58.65 ml/kg/min). It is not significant difference in the relative maximal oxygen uptake, but is significant difference between group in the absolute maximal oxygen uptake(p<0.001) 2. AT-VO₂(l/min) and AT-VO₂(ml/kg/min) in the anaerobic threshold was highest (3.71 l/min, 47.28 ml/kg/min) in Judo players, followed in order by the T.K.D players(3.29 l/min, 48.75 ml/kg/min), boxing players(2.90 l/min, 43.91 ml/kg/min) and ken-do players(2.82 l/min, 43.52 ml/kg/min). It is not significant difference in the AT-V02(ml/kg/min), but is significant difference between group in the AT-V02(l/min). (p<0.001) 3. %HRmax and %V 02max in the anaerobic threshold was not significant difference between group.

리스페달 정(리스페리돈 2㎎)에 대한 리스펜 정의 생물학적 동등성

조혜영,박은자,강현아,백승희,이석,박찬호,문재동,이용복 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.2

The purpose of the present study was to evaluate the bioequivalence of two risperidone tablets, Risperdal (Janssen Korea Co., Ltd) and Rispen (Myung In Pharm. Co., Ltd), according to the guidelines of Korea Food and Drug Administration (KFDA). The risperione release from the two risperidone formulations in vitro was tested using KP Ⅷ Apparatus Ⅱ method with various of dissolution media (pH 1.2, 4.0, 6.8 butter solution and water). Twenty four healthy male subjects, 23.33±2.10 years in age and 69.24±8.05 kg in body weight, were divided into two groups and a randomized 2×2 crossover study was employed. After one tablet containing 2 ㎎ as risperidone was orally administered, blood was taken at predetermined time intervals and the concentration of risperidone in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_(t), C_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_(t), C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Risperdal were 0.20, -1.29 and -11.09% for AUC_(t), C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.90)∼log(1.03) and log(0.84)∼log(1.09) for AUC_(t) and C_(max), respectively). Thus, the criteria of the KFDA guideline for the bioequivalence were satisfied, indicating Rispen tablet and Risperdal tablet were bioequivalent.

스프렌딜 지속정(펠로디핀 5㎎)에 대한 스타핀 지속정의 생물학적동등성

조혜영,강현아,이석,백승희,박은자,최후균,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.4

Felodipine is a calcium antagonist that lowers blood pressure by reducing peripheral resistance by means of a direct, selective action on smooth muscle in arterial resistance vessels. Furthermore, it have been approved for the effective in angina pectoris and cardiac failure. The purpose of the present study was to evaluate the bioequivalence of two felodipine extended release (ER) tablets, Splendil (YuHan Corporation) and Stapin (Hana Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). THe felodipine release from the two felodipine formulations in vitro was tested using KP Ⅷ Apparatus Ⅱ method at pH 6.5 buffer solution. Twenty six healthy male subjects, 22.73±1.78 years in age and 66.66±7.28 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After two tablets containing 5 ㎎ as felodipine were orally administered, blood sample was taken at predetermined time intervals and the concentrations of felodipine in serum were determined using column-switching HPLC method with UV detector. The dissolution profiles of two formulations were similar at pH 6.5 buffer solution. Besides, the pharmacokinetic parameters such as AUG_(t), C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_(t) and C_(max) and untransformed T_(max). The results showed that the differences between two formulations based on the Splendil were 2.53%, 1.32% and 18.32% for AUC_(t), C_(max) and T_(mzx), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.86)∼log(1.20) and long(0.89)∼long(1.23) for AUC_(t) and C_(max), respectively). Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Stapin ER tablet and Splendil ER tablet are bioequivalent.